American Lung Association Announces Call for Ideas for First-Ever Lung Cancer Interception Dream Team
New funding opportunity from Lung Association, LUNGevity, Stand Up To Cancer to research ‘interception’ of pre-cancerous cells, with potential to save lives, positively impact patients in near future
(February 7, 2017) - CHICAGO
For more information please contact:
Today the American Lung Association announced a Call for Ideas requesting research proposals that focus on early detection and interception of lung cancer for the Stand Up To Cancer – LUNGevity – American Lung Association Lung Cancer Interception Dream Team Translational Research Grant.
Issued by the American Association for Cancer Research (AACR), Stand Up To Cancer's scientific partner, the Call for Ideas focuses on lung cancer early detection and interception—catching pre-cancerous cells and blocking them from turning into cancer cells. The Lung Cancer Interception Dream Team will be the first of its kind, funding a project up to $7 million over a four-year grant term with support from the American Lung Association and its LUNG FORCE initiative, Stand Up To Cancer (SU2C) and LUNGevity Foundation.
"We already know that early detection of lung cancer is critical for survival, when more treatment options are available. However, only 16 percent of people with lung cancer are diagnosed in the earliest stages resulting in a 5-year survival rate of only 17.7 percent. This new award opens the door to revolutionary advances in lung cancer treatment through intercepting pre-cancerous cells and blocking them from developing into lung cancer," said American Lung Association National President and CEO Harold P. Wimmer. "Such a development could turn the tide against lung cancer—the leading cause of cancer deaths. The American Lung Association is proud to collaborate with Stand Up To Cancer and LUNGevity Foundation in support of a multidisciplinary Lung Cancer Interception Dream Team to make the dream of ending lung cancer a reality."
The SU2C-LUNGevity-American Lung Association Lung Cancer Interception Dream Team will span multiple disciplines and institutions – an approach that promotes the sharing of information and resources with a focus of improved outcomes for patients.
"The Lung Cancer Interception Dream Team is truly unique and designed to positively impact patients in the near future," Wimmer said. "This is a powerful opportunity to reduce the terrible toll of lung cancer on patients and their families and to ultimately save lives. The American Lung Association is pleased to announce this Call for Ideas seeking research proposals from leading researchers and innovative scientists worldwide."
The American Lung Association is the nation's leading organization working to save lives by improving lung health and preventing lung disease, and defeating lung cancer is a strategic imperative of the organization. In 2014 the American Lung Association launched LUNG FORCE, an initiative aimed at uniting the nation against lung cancer. Since then the organization has more than doubled its investment in lung cancer research. According to Wimmer, the investment in the Lung Cancer Interception Dream Team marks the organization's largest single investment in lung cancer research to date.
The deadline for the Call for Ideas is March 8, 2017, and more information about this opportunity can be found at https://proposalcentral.altum.com. To learn more about lung health research funded by the American Lung Association, visit Lung.org/research. For journalists seeking an interview with an expert about lung cancer and research, contact Allison MacMunn at [email protected] or 312-801-7628.
About the American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease, through research, education and advocacy. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to improve the air we breathe; to reduce the burden of lung disease on individuals and their families; and to eliminate tobacco use and tobacco-related diseases. For more information about the American Lung Association, a holder of the Better Business Bureau Wise Giving Guide Seal, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org.
About LUNG FORCE
LUNG FORCE is a new national movement led by the American Lung Association to unite women against lung cancer, the #1 cancer killer of women. LUNG FORCE has three priorities: 1) Make lung cancer a cause that people care about—and act on; 2) Educate and empower patients and healthcare providers and 3) Raise critical funds for lung cancer research. The American Lung Association's LUNG FORCE is nationally presented by CVS Health. Find out more at LUNGFORCE.org.
About the Stand Up To Cancer Initiative
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease.
Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late co-founder Laura Ziskin executive produced both the Sept. 5, 2008, and Sept. 10, 2010, broadcasts. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C’s president since 2011.
The American Association for Cancer Research (AACR), the world’s first and largest professional organization dedicated to advancing cancer research, is the official Scientific Partner of Stand Up To Cancer. AACR is responsible for administering the grants and providing scientific oversight in conjunction with the SU2C Scientific Advisory Committee (SAC).
For more information, visit standup2cancer.org.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR’s membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. For more information about the AACR, visit www.AACR.org.
About the LUNGevity Foundation
LUNGevity is the nation's leading lung cancer organization investing in life-saving, translational research and providing support services and education for patients and caregivers. LUNGevity's goals are three-fold (1) accelerate research to patients, (2) empower patients to be active participants in their treatment decisions, and (3) remove barriers that patients face in accessing the right treatments.
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. LUNGevity's comprehensive resources include a medically-vetted website, a toll-free Help Line in partnership with CancerCare®, a unique lung cancer navigator app, peer-to-peer matching for patients and caregivers (LUNGevity LifeLine), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our clinical trial finder tool, a Clinical Trial Ambassador program and participation with Emerging Med.
Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, please visit www.LUNGevity.org.